Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 for late-stage relapsed or refractory osteosarcoma granted FDA breakthrough therapy designation.

HANSOH PHARMA (03692) announced that GSK's GSK5764227 (GSK'227, also known as HS-20093) has been granted Breakthrough Therapy Designation (BTD) by the Food and Drug Administration (FDA) in the United States. This B7-H3 targeted antibody-drug conjugate (ADC) is being evaluated for the treatment of relapsed or refractory bone sarcoma (bone cancer) in adult patients who have received prior second-line or higher therapy. HS-20093 is a novel B7-H3 targeted ADC, composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload, and is currently undergoing multiple Phase I, II, and III clinical studies in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors.